ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

argenx and Novartis side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

argenxNovartis
studies on the registry933,902
open to participants now30212
phase 3 studies under way1694
reach primary completion within a year21128
programswith a study of their own in two years1477+7 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseargenxNovartis
Phase 1

argenx: 7 of its 14 programs at phase 1

  1. Adimanebart SC - formulation Aphase 1
  2. ARGX-124phase 1
  3. empasiprubart SC AIphase 1
  4. ARGX-109phase 1
  5. ARGX-213phase 1

and 2 more — sign in to see them all

50%

Novartis: 16 of its 77 programs at phase 1

  1. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1
  2. HJB647phase 1
  3. Gallium Ga 68 NNS309phase 1
  4. 177Lu-DFC413phase 1
  5. Actinium Ac 225-ETN029phase 1

and 11 more — sign in to see them all

21%
Phase 2

argenx: 3 of its 14 programs at phase 2

  1. FB102phase 2
  2. Anti-MuSK Agonistic Monoclonal Antibody ARGX-119phase 2
  3. ARGX-121phase 2
21%

Novartis: 35 of its 77 programs at phase 2

  1. Lutetium-177phase 2
  2. rapcabtagene autoleucelphase 2
  3. DDY391phase 2
  4. arumakimigphase 2
  5. QCZ484phase 2

and 30 more — sign in to see them all

45%
Phase 3

argenx: 2 of its 14 programs at phase 3

  1. empasiprubartphase 3
  2. adimanebartphase 3
14%

Novartis: 18 of its 77 programs at phase 3

  1. remibrutinibphase 3
  2. ianalumabphase 3
  3. iptacopanphase 3
  4. pelabresibphase 3
  5. pelacarsenphase 3

and 13 more — sign in to see them all

23%
Approved, new studies

argenx: 2 of its 14 programs at approved, new studies

  1. efgartigimod alfaapproved, new study
  2. hyaluronidase (human recombinant)approved, new study
14%

Novartis: 8 of its 77 programs at approved, new studies

  1. inclisiranapproved, new study
  2. Alpelisibapproved, new study
  3. asciminibapproved, new study
  4. secukinumabapproved, new study
  5. ruxolitinibapproved, new study

and 3 more — sign in to see them all

10%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
argenx9 readouts · 1 phase 3

argenx, Nov ’26: 1 program whose next study reaches primary completion

  1. empasiprubartphase 3 · Nov 0 · NCT06284954

argenx, Dec ’26: 4 programs whose next study reaches primary completion

  1. adimanebartphase 3 · Dec 0 · NCT07673601
  2. Adimanebart SC - formulation Aphase 1 · Dec 0 · NCT07673601
  3. ARGX-124phase 1 · Dec 31 · NCT07377396
  4. FB102phase 2 · Dec 31 · NCT06905873
··

argenx, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. efgartigimod alfaapproved, new study · Mar 0 · NCT04833894
  2. empasiprubart SC AIphase 1 · Mar 0 · NCT07612020
  3. hyaluronidase (human recombinant)approved, new study · Mar 0 · NCT06655155
····

argenx, Aug ’27: 1 program whose next study reaches primary completion

  1. Anti-MuSK Agonistic Monoclonal Antibody ARGX-119phase 2 · Aug 24 · NCT06436742
··
Novartis27 readouts · 5 phase 3

Novartis, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. inclisiranapproved, new study · Nov 27 · NCT06501443

Novartis, Dec ’26: 5 programs whose next study reaches primary completion

  1. luxdegalutamidephase 2 · Dec 3 · NCT06991556
  2. HJB647phase 1 · Dec 8 · NCT07465653
  3. gallium 68 PSMA-11phase 2 · Dec 23 · NCT05849298
  4. iptacopanphase 3 · Dec 30 · NCT06388941
  5. Lutetium-177phase 2 · Dec 30 · NCT05870579

Novartis, Jan ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. opnurasibphase 3 · Jan 25 · NCT04699188
  2. Alpelisibapproved, new study · Jan 28 · NCT05038735

Novartis, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. cipargaminphase 2 · Feb 4 · NCT07811908
  2. ganaplacidephase 3 · Feb 4 · NCT07811908
  3. remibrutinibphase 3 · Feb 22 · NCT06868212

Novartis, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PKN605phase 2 · Mar 1 · NCT07797322
  2. EDI-048phase 2 · Mar 23 · NCT07249463
  3. ianalumabphase 3 · Mar 26 · NCT05639114

Novartis, Apr ’27: 4 programs whose next study reaches primary completion

  1. arumakimigphase 2 · Apr 22 · NCT07203001
  2. DII235phase 2 · Apr 26 · NCT07235046
  3. QCZ484phase 2 · Apr 28 · NCT07610278
  4. delpacibart zotadirsenphase 3 · Apr 30 · NCT06244082

Novartis, May ’27: 3 programs whose next study reaches primary completion

  1. GIA632phase 2 · May 17 · NCT07220577
  2. luxdegalutamidephase 2 · May 25 · NCT05067140
  3. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1 · May 31 · NCT05397496
·

Novartis, Jul ’27: 3 programs whose next study reaches primary completion

  1. EYU688phase 2 · Jul 22 · NCT06006559
  2. LXE408phase 2 · Jul 22 · NCT06632600
  3. GXV-813phase 2 · Jul 29 · NCT07467993

Novartis, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zigakibartphase 3 · Aug 10 · NCT05852938
  2. YMI024phase 2 · Aug 15 · NCT07830719

Novartis, Sep ’27: 1 program whose next study reaches primary completion

  1. asciminibapproved, new study · Sep 3 · NCT04925479
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

argenx

New programs 0

None

Reached a new phase 0

None

Study stopped 1

Primary completion later 2

Novartis

New programs 5

  • pacibekitugphase 3 · first study · Nov 9 · Myocardial Infarction
  • DKB903phase 1 · first study · Nov 2 · Arthritis, Rheumatoid
  • TRB191phase 1 · first study · Oct 26 · Small Cell Lung Carcinoma
  • XEP527phase 1 · first study · Oct 26 · Schizophrenia
  • YMI024phase 2 · first study · Sep 15 · Coronary Artery Disease

Reached a new phase 1

Study stopped 6

  • remibrutinibphase 3 · terminated Nov 20“Sponsor decision based on pre-specified futility efficacy criteria being met.” · NCT06744920
  • Lutetium-177phase 1 · terminated Nov 17“Sponsor decision and not a consequence of any safety concerns.” · NCT06379217
  • pelacarsenphase 3 · terminated Nov 10“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT05900141
  • opnurasibphase 3 · terminated Nov 6“Business reasons and not based on any safety concerns.” · NCT05132075
  • ianalumabphase 2 · withdrawn Oct 15“The study was discontinued due to evolving scientific \& feasibility considerations that could adversely af…” · NCT07039422
  • pelacarsenphase 3 · withdrawn Oct 14“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT07625306

Primary completion later 6

Where they overlap

Conditions where at least two of them have programs: 7 in all. A program counts in each condition its studies name most.

ConditionargenxNovartis
Glomerulonephritis, IGAboth · compare here

argenx in Glomerulonephritis, IGA: 1 program

  1. ARGX-121phase 2

Their studies: argenx’s studies of Glomerulonephritis, IGA in search

Novartis in Glomerulonephritis, IGA: 3 programs

  1. iptacopanphase 3
  2. Atrasentanphase 3
  3. zigakibartphase 3

Their studies: Novartis’s studies of Glomerulonephritis, IGA in search

Myasthenia Gravisboth · compare here

argenx in Myasthenia Gravis: 3 programs

  1. empasiprubartphase 3
  2. efgartigimod alfaapproved, new study
  3. hyaluronidase (human recombinant)approved, new study

Their studies: argenx’s studies of Myasthenia Gravis in search

Novartis in Myasthenia Gravis: 1 program

  1. remibrutinibphase 3

Their studies: Novartis’s studies of Myasthenia Gravis in search

Purpura, Thrombocytopenic, Idiopathicboth · compare here

argenx in Purpura, Thrombocytopenic, Idiopathic: 1 program

  1. efgartigimod alfaapproved, new study

Their studies: argenx’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Novartis in Purpura, Thrombocytopenic, Idiopathic: 3 programs

  1. ianalumabphase 3
  2. Thrombopoietin Receptor Agonistphase 2
  3. eltrombopagapproved, new study

Their studies: Novartis’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Amyotrophic Lateral Sclerosisboth · compare here

argenx in Amyotrophic Lateral Sclerosis: 2 programs

  1. adimanebartphase 3
  2. Anti-MuSK Agonistic Monoclonal Antibody ARGX-119phase 2

Their studies: argenx’s studies of Amyotrophic Lateral Sclerosis in search

Novartis in Amyotrophic Lateral Sclerosis: 1 program

  1. VHB937phase 2

Their studies: Novartis’s studies of Amyotrophic Lateral Sclerosis in search

Multiple Myelomaboth · compare here

argenx in Multiple Myeloma: 1 program

  1. hyaluronidase (human recombinant)approved, new study

Their studies: argenx’s studies of Multiple Myeloma in search

Novartis in Multiple Myeloma: 2 programs

  1. pelabresibphase 3
  2. zigakibartphase 3

Their studies: Novartis’s studies of Multiple Myeloma in search

Muscular Atrophy, Spinalboth · compare here

argenx in Muscular Atrophy, Spinal: 2 programs

  1. adimanebartphase 3
  2. Anti-MuSK Agonistic Monoclonal Antibody ARGX-119phase 2

Their studies: argenx’s studies of Muscular Atrophy, Spinal in search

Novartis in Muscular Atrophy, Spinal: 1 program

  1. Onasemnogene Abeparvovec-brveapproved, new study

Their studies: Novartis’s studies of Muscular Atrophy, Spinal in search

Vitiligoboth · compare here

argenx in Vitiligo: 1 program

  1. FB102phase 2

Their studies: argenx’s studies of Vitiligo in search

Novartis in Vitiligo: 2 programs

  1. GIA632phase 2
  2. ruxolitinibapproved, new study

Their studies: Novartis’s studies of Vitiligo in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: argenx 1 of 14 · Novartis 56 of 77 programs (17 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Novartis: 7).